A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct anti-tumor effect of Zoladex.
Cassano
A
A
Istituto di Clinica Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
Astone
A
A
Garufi
C
C
Noviello
M R
MR
Pietrantonio
F
F
Barone
C
C
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000627:therapeutic use; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy*; D005260:Female; D017273:Goserelin; D006801:Humans; D008593:Menopause
D017273:Goserelin; D002064:Buserelin